NEW YORK (GenomeWeb) – WuXi Apptec announced today that it has acquired biology contract research organization HD Biosciences (HDB).
HDB is headquartered in Shanghai, China, and operates facilities in Beijing and San Diego. WuXi Apptec said that the acquisition would help strengthen its capabilities in target validation, as well as lead discovery and optimization. HDB also provides hit identification, in vivo pharmacology, and other related services.
Following the acquisition, HDB will become a wholly owned subsidiary of WuXi Apptec. Additional terms of the deal were not disclosed.
"During the past 14 years, HD Biosciences has developed into a global company with wide recognition, and this business combination is an important step in strengthening WuXi's biology and preclinical service capability," WuXi Apptec Chairman and CEO Ge Li said in a statement.